Trial Profile
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Batoprotafib (Primary) ; Nazartinib (Primary)
- Indications Colorectal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 28 Feb 2024 Results (As of March 23, 2023, n=57) assessing safety and efficacy of TNO155 in combination with spartalizumab or ribociclib in adults with advanced solid tumors presented at the ESMO Targeted Anticancer Therapies Congress 2024
- 05 Feb 2024 Planned End Date changed from 15 Apr 2025 to 16 May 2025.
- 05 Feb 2024 Planned primary completion date changed from 15 Apr 2025 to 16 May 2025.